Skip to main
  1. Stocks
  2. Integra LifeSciences Holdings
  3. Forecast
IART

IART Stock Forecast & Price Target

IART Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 0%
Buy 14%
Hold 71%
Sell 14%
Strong Sell 0%

Bulls say

Integra Lifesciences is attractive because its core businesses are showing resilience even amid near-term disruption, with Specialty Surgical posting solid Neurosurgery growth of 7% y/y organically and strong momentum in CereLink, Certas Plus, Bactiseal, and DuraSeal. Cash generation has also improved sharply, as 3Q operating cash flow reached a record $96M and free cash flow was $86M, enabling $46M of debt repayment and reducing leverage to 3.8x from 4.1x at 2Q. The completed $2.1B refinancing extends maturities, adds covenant headroom, and supports a deleveraging-first strategy, while the stock still trades at a steep discount at about 5x P/E on the 2027 EPS estimate of $2.37.

Bears say

Integra Lifesciences is viewed cautiously because its latest quarter and FY26 guide still point to disrupted operations, with Cincinnati flood losses, lingering product ship-hold and recall effects, and slightly higher interest expense pressuring the model. Management reiterated FY26 revenue of $1.634-1.654B and adj. EPS of $2.30-2.40, but gross margin is expected to be flat versus 2025 at roughly 61.3% and about 180 bps below prior levels, underscoring weaker profitability. Although 2026-27 growth catalysts exist, the outlook remains negative because share recapture, customer re-adoption, and execution risk remain uncertain, while peers trade at meaningfully higher EV/EBITDA multiples.

IART has been analyzed by 7 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 14% recommend Buy, 71% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Integra LifeSciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

IART Analyst Forecast & Price Prediction

Get the latest IART stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IART

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Integra LifeSciences Holdings (IART) Forecast

Analysts have given IART a Hold based on their latest research and market trends.

According to 7 analysts, IART has a Hold consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Integra LifeSciences Holdings (IART)


IART Analyst Forecast & Price Prediction

Get the latest IART stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IART

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IART stock data and trends